Canaccord raised the firm’s price target on Ventyx Biosciences (VTYX) to $16 from $14 and keeps a Buy rating on the shares. The firm said the target increase is associated with reduced near-term OpEx projections based on the company’s latest financial results as well as the clinical development status with less clinical trials currently ongoing, compared to 1Q and 2Q25.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTYX:
- Ventyx Biosciences Reports Q3 2025 Financial Results
- Ventyx Biosciences reports Q3 EPS (32c), consensus (45c)
- Ventyx Biosciences upgraded to Buy from Neutral at H.C. Wainwright
- Ventyx Biosciences price target raised to $14 from $9 at Oppenheimer
- Promising Phase II Trial Results of VTX3232 Bolster Buy Rating for Ventyx Biosciences